The Development of Nonthermal Plasma and Tirapazamine as a Novel Combination Therapy to Treat Melanoma In Situ

被引:3
|
作者
Yehl, Matthew [1 ]
Kucharski, Dominik [1 ]
Eubank, Michelle [1 ]
Gulledge, Brandon [1 ]
Rayan, Gamal [1 ]
Uddin, Md Gias [1 ]
Remmers, Genevieve [2 ]
Kandel, Eugene S. [3 ]
Dufaux, Douglas P. [4 ]
Hutcherson, Timothy C. [1 ]
Sexton, Sandra [3 ]
Zucker, Shoshanna N. [1 ]
机构
[1] DYouville Univ, Sch Pharm, 320 Porter Ave, Buffalo, NY 14201 USA
[2] IDEXX Labs, 1 IDEXX Dr, Westbrook, ME 04092 USA
[3] Roswell Park Comprehens Canc Ctr, 665 Elm St, Buffalo, NY 14203 USA
[4] Alfie Technol Corp, 227 Thorn Ave, Orchard Pk, NY 14127 USA
关键词
nonthermal plasma; tirapazamine; medical device; melanoma; skin cancer; gap junctions; porcine skin; VEMURAFENIB; MECHANISMS; CYTOTOXICITY; COBIMETINIB; CELLS; TUMOR; SKIN;
D O I
10.3390/cells12162113
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although melanoma accounts for only 5.3% of skin cancer, it results in >75% of skin-cancer-related deaths. To avoid disfiguring surgeries on the head and neck associated with surgical excision, there is a clear unmet need for other strategies to selectively remove cutaneous melanoma lesions. Mohs surgery is the current treatment for cutaneous melanoma lesions and squamous and basal cell carcinoma. While Mohs surgery is an effective way to remove melanomas in situ, normal tissue is also excised to achieve histologically negative margins. This paper describes a novel combination therapy of nonthermal plasma (NTP) which emits a multitude of reactive oxygen species (ROS) and the injection of a pharmaceutical agent. We have shown that the effects of NTP are augmented by the DNA-damaging prodrug, tirapazamine (TPZ), which becomes a free radical only in conditions of hypoxemia, which is often enhanced in the tumor microenvironment. In this study, we demonstrate the efficacy of the combination therapy through experiments with B16-F10 and 1205 Lu metastatic melanoma cells both in vitro and in vivo. We also show the safety parameters of the therapy with no significant effects of the therapy when applied to porcine skin. We show the need for the intratumor delivery of TPZ in combination with the surface treatment of NTP and present a model of a medical device to deliver this combination therapy. The importance of functional gap junctions is indicated as a mechanism to promote the therapeutic effect. Collectively, the data support a novel therapeutic combination to treat melanoma and the development of a medical device to deliver the treatment in situ.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Targeting Mutant BRAF in Melanoma Current Status and Future Development of Combination Therapy Strategies
    Kudchadkar, Ragini
    Paraiso, Kim H. T.
    Smalley, Keiran S. M.
    CANCER JOURNAL, 2012, 18 (02): : 124 - 131
  • [32] Development of novel autophagy inhibitors-based anticancer combination therapy
    Saleh, Yomna
    Jansson, Patric
    Sahni, Sumit
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 28 - 29
  • [33] Development of novel combination therapy for triple-negative breast cancer
    Lee, H.
    Lee, K.
    Lee, J.
    Yoon, K.
    Mohammad, A. M.
    Park, H. S.
    Park, J. S.
    Lee, S. -T.
    Sohn, J.
    BREAST, 2019, 44 : S36 - S37
  • [34] A novel combination therapy for metastatic melanoma potentiates a gap junction positive feedback mechanism.
    Bagati, Archis
    Koch, Zethan
    Hutcherson, Timothy C.
    Pechette, Joseph
    Dianat, Hossein
    Higley, Cory
    Chiu, Lisa
    Song, Yesul
    Shah, Jay
    Chazen, Elana
    Nicolais, Andrew
    Casey, Peter
    Thompson, Kyle
    Nikiforov, Mikhail A.
    Zirnheld, Jennifer
    Zucker, Shoshanna N.
    CANCER RESEARCH, 2020, 80 (19) : 58 - 58
  • [35] A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
    Yamamoto, S
    Aiken, T
    Kaneda, Y
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6250S - 6251S
  • [36] Argon Cold Plasma-A Novel Tool to Treat Therapy-resistant Corneal Infections
    Reitberger, Helena H.
    Czugala, Marta
    Chow, Catherine
    Mohr, Andreas
    Burkovski, Andreas
    Gruenert, Anja K.
    Schoenebeck, Renate
    Fuchsluger, Thomas A.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 190 : 150 - 163
  • [38] Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs
    Thein Swe
    Kevin B. Kim
    Clinical & Experimental Metastasis, 2018, 35 : 503 - 520
  • [39] Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs
    Swe, Thein
    Kim, Kevin B.
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (5-6) : 503 - 520
  • [40] Development of Nanocarrier-Based Radionuclide and Photothermal Therapy in Combination with Chemotherapy in Melanoma Cancer Treatment
    Peltek, Oleksii O.
    Karpov, Timofey E.
    Rogova, Anna
    Postovalova, Alisa
    Ageev, Eduard
    Petrov, Andrey
    Antuganov, Dmitri
    Stanzhevsky, Andrei A.
    Maistrenko, Dmitri N.
    Zuev, Dmitry
    Muslimov, Albert R.
    Timin, Alexander S.
    Zyuzin, Mikhail, V
    ACS APPLIED MATERIALS & INTERFACES, 2023, 15 (10) : 13460 - 13471